109 related articles for article (PubMed ID: 34038639)
1. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp.
Zhao J; Zhang Y; Wang M; Liu Q; Lei X; Wu M; Guo S; Yi D; Li Q; Ma L; Liu Z; Guo F; Wang J; Li X; Wang Y; Cen S
ACS Infect Dis; 2021 Jun; 7(6):1535-1544. PubMed ID: 34038639
[TBL] [Abstract][Full Text] [Related]
2. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study.
Rabie AM; Eltayb WA
Mol Biotechnol; 2024 Apr; 66(4):592-611. PubMed ID: 36690820
[TBL] [Abstract][Full Text] [Related]
3. Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2.
Bakheit AH; Saquib Q; Ahmed S; Ansari SM; Al-Salem AM; Al-Khedhairy AA
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005857
[TBL] [Abstract][Full Text] [Related]
4. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation.
Hasan MK; Kamruzzaman M; Bin Manjur OH; Mahmud A; Hussain N; Alam Mondal MS; Hosen MI; Bello M; Rahman A
Heliyon; 2021 Mar; 7(3):e06435. PubMed ID: 33693066
[TBL] [Abstract][Full Text] [Related]
5. A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity.
Min JS; Kim GW; Kwon S; Jin YH
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32727069
[TBL] [Abstract][Full Text] [Related]
6. RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19.
Machitani M; Yasukawa M; Nakashima J; Furuichi Y; Masutomi K
Cancer Sci; 2020 Nov; 111(11):3976-3984. PubMed ID: 32805774
[TBL] [Abstract][Full Text] [Related]
7. "Bucket brigade" using lysine residues in RNA-dependent RNA polymerase of SARS-CoV-2.
Tanimoto S; Itoh SG; Okumura H
Biophys J; 2021 Sep; 120(17):3615-3627. PubMed ID: 34339634
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genome replication fidelity between SARS-CoV-2 and influenza A virus in cell culture.
Kawasaki Y; Abe H; Yasuda J
Sci Rep; 2023 Aug; 13(1):13105. PubMed ID: 37567927
[TBL] [Abstract][Full Text] [Related]
9. Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
Bennett RP; Yoluç Y; Salter JD; Ripp A; Jessen HJ; Kaiser SM; Smith HC
Antiviral Res; 2023 Oct; 218():105716. PubMed ID: 37690700
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From
Uengwetwanit T; Chutiwitoonchai N; Wichapong K; Karoonuthaisiri N
Comput Struct Biotechnol J; 2022; 20():882-890. PubMed ID: 35136534
[TBL] [Abstract][Full Text] [Related]
11. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase.
Shannon A; Selisko B; Le N; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
bioRxiv; 2020 May; ():. PubMed ID: 32511380
[TBL] [Abstract][Full Text] [Related]
12. RNA: The most attractive target in recent viral diseases.
Rabie AM
Chem Biol Drug Des; 2024 Jan; 103(1):e14404. PubMed ID: 38092663
[TBL] [Abstract][Full Text] [Related]
13. Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp.
Zhou B; Chen D; Zhang T; Song C; Zhang X; Lin L; Huang J; Peng X; Liu Y; Wu G; Li J; Chen W
Biomed Pharmacother; 2024 Feb; 171():116180. PubMed ID: 38266622
[TBL] [Abstract][Full Text] [Related]
14. Promising Experimental Anti-SARS-CoV-2 Agent "SLL-0197800": The Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus.
Rabie AM; Abdel-Dayem MA; Abdalla M
ACS Omega; 2023 Oct; 8(39):35538-35554. PubMed ID: 37810715
[TBL] [Abstract][Full Text] [Related]
15. Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics.
Tóth LJ; Krejčová K; Dejmek M; Žilecká E; Klepetářová B; Poštová Slavětínská L; Bouřa E; Nencka R
Beilstein J Org Chem; 2024; 20():1029-1036. PubMed ID: 38746653
[TBL] [Abstract][Full Text] [Related]
16. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.
Agrawal L; Poullikkas T; Eisenhower S; Monsanto C; Bakku RK; Chen MH; Kalra RS
Antibodies (Basel); 2021 Jan; 10(1):. PubMed ID: 33440681
[TBL] [Abstract][Full Text] [Related]
17. Quinazoline-Schiff base conjugates:
Mansour MA; AboulMagd AM; Abdel-Rahman HM
RSC Adv; 2020 Sep; 10(56):34033-34045. PubMed ID: 35519053
[TBL] [Abstract][Full Text] [Related]
18. Targeting RdRp of SARS-CoV-2 with De Novo Molecule Generation.
Vijay A; Sreyas Adury VS; Mukherjee A
ACS Appl Bio Mater; 2024 Feb; 7(2):609-616. PubMed ID: 37566736
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase.
Chien M; Anderson TK; Jockusch S; Tao C; Kumar S; Li X; Russo JJ; Kirchdoerfer RN; Ju J
bioRxiv; 2020 Mar; ():. PubMed ID: 32511320
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potential Key Agents for Targeting RNA-Dependent RNA Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug Screening.
Ao S; Han D; Sun L; Wu Y; Liu S; Huang Y
Front Genet; 2020; 11():581668. PubMed ID: 33281876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
